{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T01:32:36Z","timestamp":1773883956445,"version":"3.50.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sodium\u2013glucose co-transporter 2 inhibitors have demonstrated renoprotective effects in patients with CKD. However, concerns remain regarding their potential effect on bone mineral metabolism. This study investigated the impact of dapagliflozin on bone health in non-diabetic patients with CKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This randomized, double-blind, placebo-controlled trial enrolled 100 non-diabetic adults with CKD and an estimated glomerular filtration rate (eGFR) of 25\u201375\u00a0ml\/min\/1.73\u00a0m2. Participants were randomized 1:1 to receive either dapagliflozin 10\u00a0mg daily or placebo for 12\u00a0months and stratified by age and eGFR. Serum creatinine, eGFR, urinary protein:creatinine ratio, calcium:creatinine ratio and phosphorus:creatinine ratio were measured at baseline and after 12\u00a0months. Bone health was assessed at the same time points using bone formation markers [bone-specific alkaline phosphatase (BSAP), total procollagen type 1 N-terminal propeptide (P1NP)] and bone resorption markers [carboxy-terminal telopeptide of type I collagen (CTX-1), tartrate-resistant acid phosphatase 5b (TRAP-5b)]. Moreover, quantitative computed tomography (QCT) was used to assess volumetric bone mineral density (vBMD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Participants had a mean age of 53.5\u00a0\u00b1\u00a011.1\u00a0years, with no significant baseline differences between groups. Dapagliflozin significantly reduced proteinuria compared with placebo (P\u00a0=\u00a0.012) without significantly affecting eGFR. Both groups experienced significant decreases in BSAP and TRAP-5b levels (P\u00a0&amp;lt;\u00a0.001), with no intergroup differences. P1NP remained stable in both groups. CTX-1 levels increased significantly in the placebo group (P\u00a0=\u00a00.032) but not in the dapagliflozin group without significant intergroup differences. No significant differences in vBMD or T-scores at any lumbar or total lumbar spine were observed between groups after 1\u00a0year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This exploratory randomized controlled trial did not demonstrate any meaningful impact of dapagliflozin on either bone turnover or QCT markers. While these findings provide reassuring preliminary evidence, larger studies are needed to definitively establish long-term bone safety of dapagliflozin in non-diabetic patients with CKD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ckj\/sfaf384","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T12:53:08Z","timestamp":1765284788000},"source":"Crossref","is-referenced-by-count":1,"title":["Impact of dapagliflozin on bone mineral metabolism in non-diabetic patients with chronic kidney disease: a randomized, double-blind, placebo-controlled study"],"prefix":"10.1093","volume":"19","author":[{"given":"Mohamed","family":"Elshayeb","sequence":"first","affiliation":[{"name":"Dialysis and Transplantation Unit, Urology and Nephrology Center, Mansoura University Department of Nephrology, , Mansoura City ,","place":["Egypt"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Abdulgalil","sequence":"additional","affiliation":[{"name":"Mansoura Nephrology and Dialysis Unit (MNDU), Mansoura University , Mansoura City ,","place":["Egypt"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amr","family":"El-Husseini","sequence":"additional","affiliation":[{"name":"Division of Nephrology & Bone and Mineral Metabolism, University of Kentucky , Lexington, KY ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammed","family":"Elhadedy","sequence":"additional","affiliation":[{"name":"Dialysis and Transplantation Unit, Urology and Nephrology Center, Mansoura University Department of Nephrology, , Mansoura City ,","place":["Egypt"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir","family":"Sally","sequence":"additional","affiliation":[{"name":"Dialysis and Transplantation Unit, Urology and Nephrology Center, Mansoura University Department of Nephrology, , Mansoura City ,","place":["Egypt"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huda","family":"Refaie","sequence":"additional","affiliation":[{"name":"Urology and Nephrology Center, Mansoura University Department of Radiology, , Mansoura City ,","place":["Egypt"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wael","family":"Mortada","sequence":"additional","affiliation":[{"name":"Clinical Chemistry Lab, Urology and Nephrology Center, Mansoura University , Mansoura City ,","place":["Egypt"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kareem","family":"Nabieh","sequence":"additional","affiliation":[{"name":"Clinical Chemistry Lab, Urology and Nephrology Center, Mansoura University , Mansoura City ,","place":["Egypt"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Sobh","sequence":"additional","affiliation":[{"name":"Dialysis and Transplantation Unit, Urology and Nephrology Center, Mansoura University Department of Nephrology, , Mansoura City ,","place":["Egypt"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"2026031808523401700_bib1","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/S0140-6736(13)60439-0","article-title":"Evolving importance of kidney disease: from subspecialty to global health burden","volume":"382","author":"Eckardt","year":"2013","journal-title":"Lancet"},{"key":"2026031808523401700_bib2","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0140-6736(21)00519-5","article-title":"Chronic kidney disease","volume":"398","author":"Kalantar-Zadeh","year":"2021","journal-title":"Lancet"},{"key":"2026031808523401700_bib3","first-page":"389","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"384","author":"Heerspink","year":"2021","journal-title":"N Engl J Med"},{"key":"2026031808523401700_bib4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Group","year":"2023","journal-title":"N Engl J Med"},{"key":"2026031808523401700_bib5","doi-asserted-by":"publisher","first-page":"4374","DOI":"10.3390\/ijms22094374","article-title":"Pleiotropic effects of sodium-glucose cotransporter-2 inhibitors: renoprotective mechanisms beyond glycemic control","volume":"22","author":"Takata","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026031808523401700_bib6","first-page":"1","article-title":"Osteoporosis prevention, diagnosis, and therapy","volume":"17","author":"NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy","year":"2000","journal-title":"NIH Consens Statement"},{"key":"2026031808523401700_bib7","doi-asserted-by":"crossref","first-page":"e10242","DOI":"10.1002\/jbm4.10242","article-title":"Mineral and electrolyte disorders with SGLT2i therapy","volume":"3","author":"Cianciolo","year":"2019","journal-title":"JBMR Plus"},{"key":"2026031808523401700_bib8","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"key":"2026031808523401700_bib9","article-title":"Canagliflozin: clinical efficacy and safety","author":"Kwon","year":"2013","journal-title":"Endocrinology and Metabolic Drugs Advisory Committee Meeting"},{"key":"2026031808523401700_bib10","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/dom.12189","article-title":"Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin","volume":"16","author":"Bolinder","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"2026031808523401700_bib11","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/jdi.13340","article-title":"Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: subanalysis of a prospective, randomized, controlled study (PRIME-V study)","volume":"12","author":"Koshizaka","year":"2021","journal-title":"J Diabetes Invest"},{"key":"2026031808523401700_bib12","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1007\/s13300-024-01634-2","article-title":"A randomized controlled trial on the effect of luseogliflozin on bone microarchitecture evaluated using HR-pQCT in elderly type 2 diabetes","volume":"15","author":"Shigeno","year":"2024","journal-title":"Diabetes Ther"},{"key":"2026031808523401700_bib13","doi-asserted-by":"publisher","first-page":"F942","DOI":"10.1152\/ajprenal.00129.2018","article-title":"A model of calcium transport and regulation in the proximal tubule","volume":"315","author":"Edwards","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026031808523401700_bib14","doi-asserted-by":"publisher","first-page":"F998","DOI":"10.1152\/ajprenal.00032.2017","article-title":"Effect of diuretics on renal tubular transport of calcium and magnesium","volume":"312","author":"Alexander","year":"2017","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026031808523401700_bib15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S2213-8587(14)70227-X","article-title":"Possible adverse effects of SGLT2 inhibitors on bone","volume":"3","author":"Taylor","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026031808523401700_bib16","doi-asserted-by":"publisher","first-page":"e99123","DOI":"10.1172\/jci.insight.99123","article-title":"Canagliflozin triggers the FGF23\/1,25-dihydroxyvitamin D\/PTH axis in healthy volunteers in a randomized crossover study","volume":"3","author":"Blau","year":"2018","journal-title":"JCI Insight"},{"key":"2026031808523401700_bib17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1210\/jc.2015-1860","article-title":"Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin","volume":"101","author":"Bilezikian","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2026031808523401700_bib18","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/dom.13103","article-title":"Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET)","volume":"20","author":"Rosenstock","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2026031808523401700_bib19","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/j.1463-1326.2012.01630.x","article-title":"Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin","volume":"14","author":"Ljunggren","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"2026031808523401700_bib20","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.3390\/medicina57121352","article-title":"Different effects of empagliflozin on markers of mineral-bone metabolism in diabetic and non-diabetic patients with stage 3 chronic kidney disease","volume":"57","author":"Masajtis-Zagajewska","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"2026031808523401700_bib21","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1210\/jc.2015-3167","article-title":"Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus","volume":"101","author":"Watts","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2026031808523401700_bib22","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"2026031808523401700_bib23","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.ekir.2022.02.022","article-title":"Low turnover renal osteodystrophy with abnormal bone quality and vascular calcification in patients with mild-to-moderate CKD","volume":"7","author":"El-Husseini","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2026031808523401700_bib24","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1007\/s00198-023-06908-2","article-title":"Effect of SGLT2 inhibitors on fractures, BMD, and bone metabolism markers in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"34","author":"Wang","year":"2023","journal-title":"Osteoporos Int"},{"key":"2026031808523401700_bib25","doi-asserted-by":"publisher","first-page":"4873","DOI":"10.3390\/ijms20194873","article-title":"Impact of diabetes mellitus on bone health","volume":"20","author":"Murray","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2026031808523401700_bib26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/oby.23331","article-title":"SGLT inhibitors on weight and body mass: a meta-analysis of 116 randomized-controlled trials","volume":"30","author":"Cheong","year":"2022","journal-title":"Obesity (Silver Spring)"},{"key":"2026031808523401700_bib27","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1359\/jbmr.2001.16.1.141","article-title":"Bone mineral changes in obese women during a moderate weight loss with and without calcium supplementation","volume":"16","author":"Jensen","year":"2001","journal-title":"J Bone Miner Res"},{"key":"2026031808523401700_bib28","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1001\/archinte.166.22.2502","article-title":"Bone mineral density response to caloric restriction\u2013induced weight loss or exercise-induced weight loss: a randomized controlled trial","volume":"166","author":"Villareal","year":"2006","journal-title":"Arch Intern Med"},{"key":"2026031808523401700_bib29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00223-002-1019-4","article-title":"Leptin, body composition and bone mineral density in premenopausal women","volume":"73","author":"Blum","year":"2003","journal-title":"Calcif Tissue Int"},{"key":"2026031808523401700_bib30","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1210\/jc.2006-0794","article-title":"Fat mass is not beneficial to bone in adolescents and young adults","volume":"92","author":"Janicka","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2026031808523401700_bib31","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1210\/jc.2006-0572","article-title":"Relationship of obesity with osteoporosis","volume":"92","author":"Zhao","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2026031808523401700_bib32","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.kint.2015.12.038","article-title":"Sodium\u2013glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis","volume":"89","author":"Rajasekeran","year":"2016","journal-title":"Kidney Int"},{"key":"2026031808523401700_bib33","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S2213-8587(21)00243-6","article-title":"Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Jongs","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026031808523401700_bib34","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S2213-8587(20)30162-5","article-title":"Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial","volume":"8","author":"Cherney","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026031808523401700_bib35","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1007\/s11255-023-03539-8","article-title":"Effect of sodium\u2013glucose transporter 2 inhibitor empagliflozin on proteinuria and kidney function progression in patients with non-diabetic glomerulonephritis: a pilot superiority randomized controlled trial","volume":"55","author":"Hammad","year":"2023","journal-title":"Int Urol Nephrol"},{"key":"2026031808523401700_bib36","doi-asserted-by":"publisher","first-page":"66","DOI":"10.2215\/CJN.04530418","article-title":"Effects of dapagliflozin on circulating markers of phosphate homeostasis","volume":"14","author":"de Jong","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026031808523401700_bib37","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1007\/s00125-016-4101-6","article-title":"Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials","volume":"59","author":"Tang","year":"2016","journal-title":"Diabetologia"},{"key":"2026031808523401700_bib38","doi-asserted-by":"publisher","first-page":"117518","DOI":"10.1016\/j.cca.2023.117518","article-title":"The levels of bone turnover markers and parathyroid hormone and their relationship in chronic kidney disease","volume":"548","author":"Xie","year":"2023","journal-title":"Clin Chim Acta"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfaf384\/65817814\/sfaf384.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/3\/sfaf384\/65817814\/sfaf384.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/3\/sfaf384\/65817814\/sfaf384.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T12:56:39Z","timestamp":1773838599000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfaf384\/8374729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfaf384","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,12,9]]},"article-number":"sfaf384"}}